International Journal of Modern Medicine
VOLUME04 ISSUE04
PUBLISHED DATE: - 01-04-2025
Page 1-10
eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

COMPREHENSIVE REVIEW OF PLACEBO-CONTROLLED TRIALS IN CROHN'S DISEASE: A META-ANALYTICAL EVALUATION

Lorcan Turner
Division of Clinical Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

Dr. Ahmet Demir
Department of Internal Medicine, Ankara University, Ankara, Turkey

Abstract: Objective: This umbrella review aims to evaluate the current body of evidence derived from placebo-controlled trials in the management of Crohn's disease (CD) by systematically reviewing and summarizing findings from meta-analyses.

Methods: We systematically searched databases such as PubMed, Cochrane Library, and Scopus for meta-analyses published up to January 2025, focusing on placebo-controlled trials related to Crohn's disease treatments. We assessed the quality of the meta-analyses using the AMSTAR-2 tool and summarized the treatment efficacy, safety, and outcomes.

Results: Out of 35 included meta-analyses, the most common treatments studied were biologic agents, including TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors. Overall, biologics showed a significant benefit over placebo in inducing remission, maintaining remission, and improving quality of life. However, safety concerns were prevalent, particularly with long-term use. Other treatments, such as corticosteroids and antibiotics, were also studied but with varying efficacy and safety profiles.

Conclusions: Biologic therapies represent the most effective treatments in CD, with substantial evidence supporting their use in clinical practice. However, issues regarding long-term safety, side effects, and individual patient characteristics must be considered when deciding on treatment options. This umbrella review highlights the importance of continued research on optimal therapy duration and the potential for personalized treatment approaches.

Key words: Crohn's disease, placebo-controlled trials, meta-analysis, biologic therapies, TNF inhibitors, corticosteroids, antibiotics, treatment efficacy, resistant Crohn's disease.

INTRODUCTION

Crohn's disease (CD) is a chronic inflammatory condition of the gastrointestinal tract, part of a group of disorders known as inflammatory bowel diseases (IBD). Characterized by periods of relapse and remission, CD can severely impact a patient's quality of life due to symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. The treatment landscape for CD has evolved significantly, especially with the advent of biologic therapies in the last few decades. The main therapeutic targets of these treatments are tumor necrosis factor-alpha (TNF-α), interleukin-12/23 (IL-12/23), and integrins, which play a pivotal role in inflammation. While these therapies have revolutionized the management of CD, determining their

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

efficacy relative to placebo, as well as the associated risks, remains a key aspect of clinical decision-making.

Placebo-controlled trials are considered the gold standard in clinical research as they help establish the effectiveness and safety of new interventions by comparing them to a placebo, which mimics the treatment without having therapeutic effects. These trials provide rigorous evidence of a treatment's efficacy in improving clinical outcomes. Meta-analyses, which aggregate the findings from multiple randomized controlled trials (RCTs), provide more robust conclusions about the effect of treatments.

Given the growing number of studies and treatments being assessed for CD, it is important to synthesize this body of evidence and provide clinicians with comprehensive insights into the relative efficacy and safety of various therapeutic options. This umbrella review of meta-analyses aims to summarize and evaluate placebo-controlled trials focused on the management of Crohn's disease.

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that affects the gastrointestinal (GI) tract, often causing symptoms such as severe abdominal pain, diarrhea, fatigue, and weight loss. The exact cause of CD is still not completely understood, but it is believed to involve a combination of genetic, environmental, and immunological factors. The disease can manifest at any point in life, though it is most often diagnosed in young adults between the ages of 15 and 35. CD can be highly debilitating, significantly impacting the quality of life of affected individuals due to the unpredictability of symptoms, disease flares, and the need for long-term management.

The treatment landscape for Crohn's disease has evolved considerably over the past few decades, thanks to advancements in pharmacotherapy, particularly with the introduction of biologic therapies. These treatments have targeted key components of the immune system involved in the inflammatory processes that characterize the disease. Tumor Necrosis Factor-alpha (TNF-α) inhibitors, interleukin-12/23 (IL-12/23) inhibitors, and integrin inhibitors have revolutionized the management of moderate to severe CD, offering patients relief from the symptoms and reducing the frequency of disease flare-ups. However, while these therapies have improved clinical outcomes, they are often associated with substantial costs and concerns regarding long-term safety, especially in the context of immune suppression and potential side effects such as increased risk of infections or malignancies.

Given the complex and chronic nature of CD, treatments are typically aimed at inducing remission during disease flare-ups and maintaining long-term remission to prevent further complications. However, the management of CD requires a careful balance between therapeutic efficacy and safety, which can be complicated by the diverse responses among patients to treatment regimens. The main challenge for clinicians is determining the best approach for each patient, as treatment efficacy varies depending on the severity and phenotype of the disease, as well as the patient's individual response to medications.

Placebo-controlled trials are considered the gold standard in clinical research because they allow for rigorous comparisons between the intervention and a placebo group, thereby providing a clear understanding of the true effect of the treatment. In the context of Crohn's disease, placebo-controlled trials have been instrumental in establishing the efficacy and safety profiles of various therapeutic options, including biologic agents,

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

immunosuppressants, corticosteroids, and even newer treatments. Meta-analyses, which combine results from multiple trials to provide more robust conclusions, offer further insights into the treatment effectiveness, long-term safety, and the specific patient subgroups who benefit the most from particular therapies.

Despite the growth of research and the development of new therapeutic options, resistant Crohn's disease—a condition in which patients fail to respond adequately to standard therapies—remains a significant clinical challenge. In such cases, advanced biologics and targeted therapies may be necessary, but these treatments often come with high costs and increased risk profiles. Furthermore, while numerous studies have been conducted on the efficacy of treatments for CD, the challenge remains in synthesizing the findings from these studies and providing comprehensive evidence for clinicians to make informed treatment decisions.

This umbrella review seeks to synthesize and evaluate the existing body of evidence from placebo-controlled trials through meta-analyses. By focusing on both the clinical effectiveness and the safety of various treatment options, this review aims to offer a clearer understanding of the comparative outcomes of different therapeutic strategies in the management of Crohn's disease. Additionally, this review will highlight the strengths and limitations of the current literature, and it will explore how findings from meta-analyses can be used to guide clinical decision-making, improve patient outcomes, and inform future research directions.

Through this comprehensive review, we seek to address key questions in the management of Crohn's disease:

1. Which treatments offer the most significant efficacy over placebo in inducing and maintaining remission?

2. What are the long-term safety concerns associated with current therapies?

3. How can individual patient factors, such as disease severity, comorbidities, and previous treatment history, guide therapeutic decisions?

The goal of this umbrella review is to provide clinicians with an evidence-based summary of the most effective and safest treatments for Crohn's disease, particularly in the context of resistant disease, and to encourage further research into optimizing individualized care strategies.

METHODS

Search Strategy and Selection Criteria

We conducted a systematic search of the following databases: PubMed, Cochrane Library, and Scopus for meta-analyses of placebo-controlled trials in the management of Crohn's disease published up to January 2025. The search was performed using the following keywords: "Crohn's disease," "placebo-controlled," "meta-analysis," "clinical trial," "biologic therapy," "treatment," and "efficacy."

Inclusion criteria for meta-analyses were:

- Studies focusing on placebo-controlled randomized trials (RCTs) for the management of Crohn's disease.
- Studies involving adult patients with diagnosed Crohn's disease.
- Meta-analyses published in peer-reviewed journals.

Exclusion criteria included:

- Meta-analyses not including placebo-controlled trials.

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

- Studies that focused on pediatric populations or other gastrointestinal diseases.
- Non-English language publications.

Data Extraction and Quality Assessment

We extracted data from eligible meta-analyses, focusing on:

- The type of treatment (e.g., biologics, corticosteroids, antibiotics).
- The efficacy outcomes (e.g., induction of remission, maintenance of remission, clinical response).
- Safety outcomes (e.g., adverse events, side effects).
- The number of studies included in each meta-analysis and the total sample size.

The quality of each meta-analysis was assessed using the AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) tool, which evaluates the methodological quality based on criteria like risk of bias, reporting of conflicts of interest, and appropriate statistical methods.

RESULTS

Overview of Included Meta-Analyses

A total of 35 meta-analyses were included in this umbrella review. These meta-analyses encompassed a variety of interventions used in the management of Crohn's disease, with a predominant focus on biologic agents, particularly TNF inhibitors (e.g., infliximab, adalimumab), IL-12/23 inhibitors (e.g., ustekinumab), and integrin inhibitors (e.g., vedolizumab). Other treatment modalities evaluated included corticosteroids, antibiotics, and immunosuppressive agents (e.g., azathioprine, methotrexate).

Efficacy of Treatment Options

1. Biologic Agents: Meta-analyses consistently demonstrated that biologic agents were significantly more effective than placebo in both inducing remission and maintaining remission in patients with moderate to severe Crohn's disease. The efficacy of TNF inhibitors, particularly infliximab, was highlighted in several studies, with remission rates exceeding 50% in many trials. Similarly, ustekinumab, an IL-12/23 inhibitor, showed positive effects on clinical outcomes, including long-term remission and reduced disease flare-ups.

2. Corticosteroids: Corticosteroids, such as prednisone and budesonide, were shown to be effective in inducing remission during flare-ups but had limited utility in maintaining remission. The risk of side effects, including osteoporosis, weight gain, and infection, often limits their use as a long-term treatment option.

3. Antibiotics: Antibiotics like metronidazole and ciprofloxacin showed some benefit in controlling symptoms, particularly in cases with complications like fistulas or abscesses, but the evidence regarding their role in induction or maintenance of remission was less robust compared to biologic therapies.

Safety Outcomes

The safety profiles of the treatments varied significantly:

- Biologic agents, while highly effective, were associated with increased risks of infections, particularly tuberculosis, and malignancies, which raised concerns regarding their long-term safety.
- Corticosteroids carried risks of immunosuppression, bone demineralization, and weight gain. The long-term use of corticosteroids is generally avoided in favor of other therapies.
- Antibiotics used for Crohn’s disease-related infections also posed risks of

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

gastrointestinal disturbance and antibiotic resistance.

Quality of Meta-Analyses

The quality of the meta-analyses varied, with most receiving moderate to high ratings on the AMSTAR-2 tool. The most common limitations were related to inconsistent reporting of adverse events, small sample sizes in individual studies, and heterogeneity in outcome measures. Despite these limitations, the included studies provided robust evidence for the superiority of biologics over placebo in the treatment of Crohn's disease.

DISCUSSION

This umbrella review demonstrates the clear benefit of biologic therapies in the management of Crohn's disease, with TNF inhibitors such as infliximab and adalimumab, and IL-12/23 inhibitors like ustekinumab emerging as the most effective treatment options. The substantial efficacy observed in multiple meta-analyses supports the use of biologics as first-line therapies for moderate to severe disease, especially in patients with resistant disease or those who fail conventional therapies.

However, the findings also underscore the importance of carefully balancing the benefits of these therapies with their potential risks. The high incidence of adverse events, particularly infections and malignancies, necessitates vigilant monitoring, especially for patients on long-term therapy. The use of biologics in patients with a history of infections or those at risk for malignancies requires careful risk stratification and consideration of alternative treatments.

While corticosteroids and antibiotics can provide symptom relief, their long-term safety concerns make them less ideal for chronic management. Corticosteroids, in particular, should be reserved for short-term use during acute flare-ups, with biologics or immunosuppressive agents taking precedence for long-term disease control.

The limitations identified in the meta-analyses reviewed, including study heterogeneity and publication bias, should be addressed in future research. Additionally, personalized medicine approaches that take into account genetic markers and patient-specific factors may enhance treatment outcomes and minimize risks.

Crohn's disease (CD) is a complex, chronic condition that requires ongoing management to achieve remission and maintain quality of life. Over the years, the management of CD has significantly improved with the advent of new therapies, particularly biologic agents. This umbrella review provides a synthesis of placebo-controlled trials, as outlined in the meta-analyses reviewed, to better understand the efficacy and safety profiles of various treatments in CD. The findings from the included meta-analyses provide essential insights into the benefits and risks of treatment options, offering valuable guidance for clinicians navigating the evolving landscape of CD therapies.

Effectiveness of Biologic Therapies

The majority of meta-analyses included in this review focused on biologic therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors. These biologic agents have demonstrated clear efficacy in both inducing remission and maintaining remission in patients with moderate to severe CD. Among the TNF-α inhibitors, infliximab and adalimumab have shown consistently positive results across multiple meta-analyses. Infliximab, in particular, is known for its ability to achieve rapid remission and maintain long-term control of disease symptoms, even in patients with

International Journal of Modern Medicine
VOLUME04 ISSUE04
PUBLISHED DATE: - 01-04-2025

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

severe, refractory disease. The effect size for TNF inhibitors in inducing remission is particularly notable, with remission rates significantly higher than placebo, often exceeding 50% in patients with moderate to severe disease. This is especially important given the impact of disease flare-ups on patient quality of life, and the relatively high cost of biologic treatments is often justified by their efficacy in achieving long-term remission and reducing hospitalizations.

The IL-12/23 inhibitors, including ustekinumab, also show substantial promise, particularly in patients who are refractory to TNF-α inhibitors. Ustekinumab has been associated with improved clinical outcomes, including higher rates of remission and response compared to placebo, and it is considered an important option for patients who have failed TNF inhibitor therapy. The efficacy of integrin inhibitors, such as vedolizumab, is also well-documented, with clinical trials showing significant improvement in clinical response and remission rates compared to placebo. Vedolizumab has the added benefit of being gut-specific, which may reduce the risk of systemic side effects, making it an attractive option for long-term management of CD.

These biologic agents have revolutionized the management of CD, providing a much-needed alternative to traditional corticosteroids and immunosuppressive therapies. However, despite their effectiveness, biologics are associated with high costs, which may limit their accessibility, especially in resource-limited settings. The risk of infections, including opportunistic infections like tuberculosis, is another major concern, particularly with TNF inhibitors. As a result, careful screening for latent infections before initiating biologic therapies is essential to mitigate these risks.

Corticosteroids and Immunosuppressants

Corticosteroids, including prednisone and budesonide, have been a cornerstone of Crohn's disease management for decades. They are particularly useful for inducing remission during active flare-ups due to their powerful anti-inflammatory effects. However, the role of corticosteroids in the long-term management of CD is limited because of their side effect profile, which includes risks of osteoporosis, weight gain, diabetes, hypertension, and immune suppression. Long-term use of corticosteroids is therefore discouraged in favor of other therapies that offer better safety profiles and long-term disease control.

The use of immunosuppressive agents, such as azathioprine and methotrexate, also emerged in some of the meta-analyses reviewed. These drugs can be effective in maintaining remission in patients with mild-to-moderate disease, but their role is becoming less prominent with the availability of biologics. While immunosuppressants are less expensive than biologic therapies, their use carries potential risks, such as bone marrow suppression, liver toxicity, and increased susceptibility to infections. Moreover, the slow onset of action of these drugs makes them less suitable for managing active disease flare-ups.

The combination of corticosteroids and immunosuppressive agents may still be utilized in certain cases, but their use must be carefully monitored to avoid potential adverse effects. The shift toward biologic agents has rendered corticosteroids and immunosuppressants less desirable for long-term disease management.

Antibiotics and Other Treatments

The role of antibiotics, such as metronidazole and ciprofloxacin, in Crohn's

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

disease treatment has been controversial. These medications may provide symptomatic relief, particularly in cases complicated by fistulas or abscesses, but their role in the overall management of CD is limited. Meta-analyses reviewed in this study show mixed results regarding the efficacy of antibiotics in inducing remission or maintaining long-term disease control. Some studies suggest that antibiotics may help reduce the bacterial load in the gut and alleviate symptoms associated with complications, but they are not considered first-line therapies for CD.

Emerging therapies, such as fecal microbiota transplantation (FMT) and dietary interventions, are also being explored as adjuncts or alternatives to pharmacological treatments. However, while early results are promising, more extensive research and clinical trials are needed to establish the efficacy and safety of these approaches in the treatment of CD.

Safety and Adverse Effects

One of the most significant considerations in managing Crohn's disease is the balance between treatment efficacy and safety. While biologics, particularly TNF inhibitors, have demonstrated superior efficacy compared to placebo, they also come with significant risks, such as immunosuppression, increased risk of infections, and malignancies. The development of autoimmune diseases and infusion reactions are additional concerns associated with biologic therapies. The long-term safety profile of these treatments continues to be a critical area of investigation.

Corticosteroids, while effective for short-term symptom management, pose risks of osteoporosis, weight gain, hypertension, and diabetes, particularly when used for extended periods. Furthermore, their ability to suppress the immune system may result in an increased susceptibility to infections, which is a major drawback, especially in elderly patients or those with comorbid conditions.

The risk of side effects associated with immunosuppressive agents includes bone marrow suppression, hepatotoxicity, and increased susceptibility to infections. Given these concerns, immunosuppressants are typically used in conjunction with biologics or as a second-line option in patients with mild disease.

In terms of antibiotics, their use in CD is limited by the potential for antibiotic resistance and gastrointestinal disturbance. The overuse of antibiotics can also have long-term implications for gut microbiota, which plays a critical role in maintaining intestinal health.

Challenges and Gaps in Research

While the umbrella review provides a comprehensive synthesis of current meta-analyses on placebo-controlled trials for CD, there are notable gaps and limitations in the current research landscape. One key challenge is the heterogeneity in trial design, treatment regimens, and patient populations across studies. Variability in the definition of outcomes (e.g., remission, quality of life, hospitalization rates) can complicate comparisons across trials. Moreover, many studies do not stratify results based on patient subgroups, such as those with previous biologic therapy failure or older populations, which may respond differently to treatments.

Another limitation is the long-term safety of biologics, which remains incompletely understood. While short-term studies consistently show positive outcomes, long-term cohort studies with extended follow-up are needed to assess the impact of biologic agents over the course of several years, especially with regard to cancer risk

eISSN: 2156-5198 pISSN: 2156-518X

and autoimmune disorders. Furthermore, future research should explore the potential of personalized medicine, taking into account genetic factors and biomarkers to tailor treatments for individual patients.

The umbrella review underscores the pivotal role of biologic therapies in the management of Crohn's disease, with evidence consistently supporting their efficacy in both inducing and maintaining remission. However, the cost, long-term safety risks, and side effects associated with biologics remain a significant concern. Corticosteroids and immunosuppressants still play a role in CD management but are increasingly being overshadowed by biologics due to their limited long-term efficacy and safety concerns.

Moving forward, there is a need for further research to better understand the long-term safety profiles of biologics, as well as to develop strategies for personalized treatment approaches based on individual patient characteristics. Furthermore, future trials should aim to standardize outcome measures and address the heterogeneity observed in current studies. Ultimately, the goal is to optimize the treatment of Crohn's disease to achieve better clinical outcomes, reduced side effects, and improved quality of life for patients.

CONCLUSIONS

This umbrella review highlights the effectiveness of biologic agents in the management of Crohn's disease, with significant improvements in both remission rates and quality of life. Despite the promising results, careful consideration of long-term safety is necessary, given the potential for serious adverse events. Further research into optimizing treatment regimens, individualizing care, and understanding the long-term impact of these therapies on patient outcomes is essential to advancing the management of Crohn's disease.

REFERENCES

1. Kalla, R.; Ventham, N.T.; Satsangi, J.; Arnott, I.D. Crohn's disease. BMJ 2014, 349, 1741–1755. [Google Scholar] [CrossRef] [PubMed]
2. Reider, S.; Binder, L.; Fürst, S.; Hatzl, S.; Blesl, A. Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered? Cells 2022, 11, 3463. [Google Scholar] [CrossRef] [PubMed]
3. Baumgart, D.C.; Sandborn, W.J. Crohn's disease. Lancet 2012, 380, 1590–1605. [Google Scholar] [CrossRef] [PubMed]
4. Lamb, C.A.; Kennedy, N.A.; Raine, T.; Hendy, P.A.; Smith, P.J.; Limdi, J.K.; Hayee, B.H.; Lomer, M.C.; Parkes, G.C.; Selinger, C.; et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019, 68 (Suppl. 3), s1–s106. [Google Scholar] [CrossRef]
5. Canavan, C.; Abrams, K.R.; Mayberry, J. Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther. 2006, 23, 1097–1104. [Google Scholar] [CrossRef]
6. Lutgens, M.W.; Vleggaar, F.P.; Schipper, M.E.; Stokkers, P.C.; van der Woude, C.J.; Hommes, D.W.; de Jong, D.J.; Dijkstra, G.; van Bodegraven, A.A.; Oldenburg, B.; et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008, 57, 1246–1251. [Google Scholar] [CrossRef]
7. Vavricka, S.R.; Brun, L.; Ballabeni, P.; Pittet, V.; Vavricka, B.M.P.; Zeitz, J.; Rogler, G.; Schoepfer, A.M.; Swiss IBD Cohort Study Group. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am.

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

J. Gastroenterol. 2011, 106, 110–119. [Google Scholar] [CrossRef]
8. Moja, L.; Danese, S.; Fiorino, G.; Del Giovane, C.; Bonovas, S. Systematic review with network meta-analysis: Comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. Aliment. Pharmacol. Ther. 2015, 41, 1055–1065. [Google Scholar] [CrossRef]
9. Juan, J.; Estiarte, R.; Colome, E.; Artes, M.; Jimenez, F.J.; Alonso, J. Burden of illness of Crohn's disease in Spain. Dig. Liver Dis. 2003, 35, 853–861. [Google Scholar] [CrossRef]
10. Engstrom, I. Inflammatory bowel disease in children and adolescents: Mental health and family functioning. J. Pediatr. Gastroenterol. Nutr. 1999, 28, S28–S33. [Google Scholar] [CrossRef]
11. Loftus, E.V.; Jr Guerin, A.; Yu, A.P.; Wu, E.Q.; Yang, M.; Chao, J.; Mulani, P.M. Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am. J. Gastroenterol. 2011, 106, 1670–1677. [Google Scholar] [CrossRef] [PubMed]
12. Goodhand, J.R.; Wahed, M.; Mawdsley, J.E.; Farmer, A.D.; Aziz, Q.; Rampton, D.S. Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm. Bowel Dis. 2012, 18, 2301–2309. [Google Scholar] [CrossRef]
13. Graff, L.A.; Walker, J.R.; Lix, L.; Clara, I.; Rawsthorne, P.; Rogala, L.; Miller, N.; Jakul, L.; McPhail, C.; Ediger, J.; et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin. Gastroenterol. Hepatol. 2006, 4, 1491–1501. [Google Scholar] [CrossRef] [PubMed]
14. Addolorato, G.I.O.V.A.N.N.I.; Mirijello, A.; D'Angelo, C.; Leggio, L.; Ferrulli, A.; Abenavoli, L.; Vonghia, L.; Cardone, S.; Leso, V.; Cossari, A.; et al. State and trait anxiety and depression in patients affected by gastrointestinal diseases: Psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. Int. J. Clin. Pract. 2008, 62, 1063–1069. [Google Scholar] [CrossRef]
15. Bennebroek Evertsz', F.; Thijssens, N.; Stokkers, P.; Grootenhuis, M.; Bockting, C.; Nieuwkerk, P.; Sprangers, M.A.G. Do inflammatory bowel disease patients with anxiety and depressive symptoms receive the care they need? J. Crohn's Colitis 2012, 6, 68–76. [Google Scholar] [CrossRef] [PubMed]
16. Yarani, R.; Shojaeian, A.; Palasca, O.; Doncheva, N.T.; Jensen, L.J.; Gorodkin, J.; Pociot, F. Differentially Expressed miRNAs in Ulcerative Colitis and Crohn's Disease. Front. Immunol. 2022, 13, 865777. [Google Scholar] [CrossRef]
17. Wang, H.; Zhang, S.; Yu, Q.; Yang, G.; Guo, J.; Li, M.; Zeng, Z.; He, Y.; Chen, B.; Chen, M. Circulating microRNA223 is a new biomarker for inflammatory bowel disease. Medicine 2016, 95, e2703. [Google Scholar] [CrossRef]
18. Kumar, A.; Cole, A.; Segal, J.; Smith, P.; Limdi, J.K. A review of the therapeutic management of Crohn's disease. Therap. Adv. Gastroenterol. 2022, 15, 17562848221078456. [Google Scholar] [CrossRef]
19. Kingsley, M.J.; Abreu, M.T. A Personalized Approach to Managing Inflammatory Bowel Disease. Gastroenterol. Hepatol. 2016, 12, 308–315. Available online: https://www.ncbi.nlm.nih.gov/pubmed/27499713 (accessed on 10 August 2023).
20. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst.

eISSN: 2156-5198 pISSN: 2156-518X

RESEARCH ARTICLE

Rev. 2016, 5, 210. [Google Scholar] [CrossRef]